sirolimus + mycophenolate mofetil + steroids + anti-IL2 antibody

A combination immunosuppressive regimen comprising **sirolimus**, **mycophenolate mofetil**, **steroids** (typically glucocorticoids), and an **anti-IL2 antibody** (e.g., basiliximab or daclizumab) used primarily for the prevention of acute rejection in organ transplantation, particularly kidney and pancreas transplants. **Sirolimus** acts as an mTOR inhibitor to block T-cell proliferation, **mycophenolate mofetil** is an inosine monophosphate dehydrogenase inhibitor that suppresses lymphocyte proliferation, **steroids** function as broad anti-inflammatory agents modulating multiple immune signaling pathways, and **anti-IL2 antibodies** block the interleukin-2 receptor (CD25) to prevent T-cell activation. This regimen is often selected for its complementary mechanisms that collectively provide effective immunosuppression while reducing calcineurin inhibitor-associated nephrotoxicity[1][3].